Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review
Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N
Record ID 32011000631
English
Authors' objectives:
This review will examine the evidence for the effectiveness of these drugs in NAFLD.
Authors' recommendations:
Study finds that the insulin-sensitiser pioglitazone, as a treatment for non-alcoholic fatty liver disease (NAFLD), shows some improvements in liver histology and other parameters but the newer agents, the glucagon-like peptide-1 analogues, may be more worthy of future trials. The review suggests that the non-alcoholic steatohepatitis stage of NAFLD is most in need of drug trials.
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/2288
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Hypoglycemic Agents
- Insulin
- Insulin Resistance
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2011 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.